A Phase II Trial of Osimertinib in the Second-Line Treatment of Non-small Cell Lung Cancer with the EGFR T790M Mutation, Detected from Circulating Tumor DNA: LiquidLung-O-Cohort 2

समान संसाधन

• A Phase II Trial of Osimertinib as the First-Line Treatment of Non–Small Cell Lung Cancer Harboring Activating EGFR Mutations in Circulating Tumor DNA: LiquidLung-O-Cohort 1
  द्वारा: Park, Cheol-Kyu, और अन्य
  प्रकाशित: (2021)
• Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
  द्वारा: Mok, T.S., और अन्य
  प्रकाशित: (2016)
• The different path of T790M-positive EGFR-mutant lung cancer
  द्वारा: Yoon, Shinkyo, और अन्य
  प्रकाशित: (2018)
• Successful osimertinib treatment for leptomeningeal carcinomatosis from lung adenocarcinoma with the T790M mutation of EGFR
  द्वारा: Sakai, Hitomi, और अन्य
  प्रकाशित: (2017)
• EGFR T790M detection and osimertinib treatment response evaluation by liquid biopsy in lung adenocarcinoma patients with acquired resistance to first generation EGFR tyrosine kinase inhibitors
  द्वारा: Li, Chenguang, और अन्य
  प्रकाशित: (2018)